One cell therapy,starting in myeloma.
Phase 1 of evencaleucel is complete, and we are preparing the next clinical study.
01Programs
One cell therapy, starting where residual disease is best defined.
Our lead candidate, evencaleucel, is in multiple myeloma after stem cell transplant. Three further candidates, in
acute myeloid leukemia and solid tumors, are in preclinical development.
ProgramIndicationPreclinicalPhase 1Phase 2Phase 3
evencaleucelAutologous NK cellsMultiple myeloma, post-transplant with residual diseasePhase 1 complete · preparing the next clinical studySee our clinical progress →
NOK02Autologous NK cellsAcute myeloid leukemia (AML)Preclinical
NOK03Autologous NK cellsSolid tumorsPreclinical
NOK04Autologous NK cellsSolid tumorsPreclinical
02Multiple myeloma
Post-transplant myeloma leaves a high-risk window for relapse.
NOK's lead program targets multiple myeloma after autologous stem cell transplant (ASCT), when disease burden is
low and patient vulnerability is high.
Induction therapy
Reduce tumor burden
Stem cell transplant
Intensive therapy to deepen response
NOK window
NK cells to target residual disease
Maintenance therapy
Prolong remission and delay relapse
03The next study
Designed to test therapeutic efficacy.
Building on Phase 1, we are preparing the next clinical study of evencaleucel in post-transplant multiple
myeloma, planned to focus on residual disease and durability of response.
Primary clinical questionCan NOK deepen MRD response?
- Patient population
- Post-transplant multiple myeloma patients with residual disease or MRD risk
- NOK intervention
- Repeat autologous NK cell dosing without lymphodepletion
- Key readouts
- MRD conversion and depth
- Durability of MRD response
- Progression-free survival and relapse
- Safety and repeat dosing
A positive study would validate NOK's consolidation strategy and establish a path toward registrational development.